Albireo Pharma, Inc.
ALBODelisted Mar 2, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001322505
Albireo Pharma, Inc. was delisted on Mar 2, 2023; its insiders filed their last Form 4 on Mar 3, 2023; 96 institutions reported holding it in 13F filings for Q4 2022, worth $401.7M in total; no superinvestor held it.
Q1 2022 vs. Q4 2021
How the institutions holding Albireo Pharma, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 96 | 109 | +13 |
| Shares | 15.6M | 16.6M | +1.04M (+6.7%) |
| Value | $362.5M | $495.4M | +$132.9M (+36.7%) |
New holders (21)
Institutions that held Albireo Pharma, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 518,342 | $15.5M | 4.74% |
| Tang Capital Management LLC | 467,702 | $14.0M | 2.82% |
| Nicholas Investment Partners, LP | 439,235 | $13.1M | 0.93% |
| OrbiMed Advisors LLC | 194,000 | $5.79M | 0.09% |
| Silver Oak Securities, Inc | 23,795 | $836.0K | 0.17% |
| Renaissance Technologies LLC | 9,600 | $286.0K | 0.00% |
| AdvisorShares Investments LLC | 9,066 | $270.0K | 0.04% |
| Ergoteles LLC | 8,288 | $247.0K | 0.01% |
| Grimes & Company, Inc. | 8,191 | $244.0K | 0.01% |
| Burney Co | 7,976 | $238.0K | 0.01% |
| UBS Asset Management Americas Inc | 7,337 | $218.9K | 0.00% |
| Invesco Ltd. | 6,780 | $203.0K | 0.00% |
| Voya Investment Management LLC | 6,772 | $202.0K | 0.00% |
| Amalgamated Bank | 2,602 | $78.0K | 0.00% |
| Amalgamated Financial Corp. | 2,602 | $78.0K | 0.00% |
| Lazard Asset Management LLC | 2,532 | $75.0K | 0.00% |
| Russell Investments Group, Ltd. | 1,238 | $36.0K | 0.00% |
| Steward Partners Investment Advisory, LLC | 700 | $21.0K | 0.00% |
| Allspring Global Investments Holdings, LLC | 170 | $5.00K | 0.00% |
| Lindbrook Capital, LLC | 19 | $1.00K | 0.00% |
| CWM, LLC | 5 | $0 | 0.00% |
Sold out (8)
Institutions that held Albireo Pharma, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Artal Group S.A. | 600,000 | $14.0M |
| Marshall Wace, LLP | 129,126 | $3.01M |
| Baker Bros. Advisors LP | 104,521 | $2.43M |
| Man Group plc | 22,889 | $533.0K |
| Gsa Capital Partners LLP | 20,782 | $484.0K |
| ExodusPoint Capital Management, LP | 12,547 | $292.0K |
| Weiss Multi-Strategy Advisers LLC | 8,961 | $209.0K |
| Simplex Trading, LLC | 1,125 | $26.0K |